Iron Supplementation: Bioavailability, Forms, and Why Most Supplements Fall Short

This content is for educational purposes only and is not a substitute for personalised nutrition advice from a qualified dietitian or healthcare professional.

Iron deficiency is the most common nutritional deficiency worldwide, yet the gap between supplementing and actually correcting deficiency is wider than most people, and many clinicians, appreciate. Absorption rates vary by a factor of ten depending on the form of iron, what you eat alongside it, your individual gut environment, and a hormone called hepcidin that most supplement labels never mention. Understanding the science behind iron bioavailability explains why so many women take iron tablets for months and still feel exhausted.

Haem vs Non-Haem Iron: Not All Iron Is Equal

Dietary iron arrives in two structurally distinct forms, and the body handles them through completely different mechanisms.

Haem iron is found in animal muscle tissue (red meat, poultry, and fish. It is bound within a porphyrin ring, which allows it to enter intestinal cells intact via a dedicated transporter (HCP1/PCFT). Because it bypasses the usual conversion and competing-inhibitor pathways, haem iron is absorbed at roughly 15–35%, with a commonly cited mean of around 25%. Crucially, absorption of haem iron is relatively stable regardless of what else you eat with it) it is not significantly blocked by tannins, phytates, or calcium.

Non-haem iron dominates in plant foods (legumes, fortified cereals, leafy greens, tofu) and in almost every iron supplement on the market. It must first be reduced from ferric (Fe³⁺) to ferrous (Fe²⁺) form before it can be taken up by the divalent metal transporter DMT-1 in the gut wall. This conversion step is inefficient and highly sensitive to dietary context. Absorption ranges from as low as 2% to as high as 20% depending on what enhancers and inhibitors are present.

This gap matters enormously when designing a supplementation strategy. A 100 mg non-haem iron tablet may deliver only 2–5 mg of absorbed iron in a suboptimal context, roughly equivalent to a 15 mg dose absorbed at 20% under optimal conditions.

Absorption Enhancers: Getting More from Non-Haem Iron

Several dietary compounds improve non-haem iron absorption substantially.

Vitamin C (ascorbic acid) is the most potent enhancer. It reduces ferric to ferrous iron in the gut lumen and chelates the ferrous ion, keeping it soluble and preventing it from forming insoluble complexes with other food components. Studies have shown vitamin C can increase non-haem iron absorption by two to four times. Taking an iron supplement with 200–500 mg of vitamin C, either as a separate tablet or via orange juice, meaningfully improves uptake.

The "meat factor" describes a poorly characterised component of animal muscle tissue that enhances non-haem iron absorption even when haem iron itself is not the source. Adding a small portion of meat (as little as 75 g) to a meal has been shown to roughly double absorption of co-consumed non-haem iron, possibly through partial digestion peptides that chelate iron in a bioavailable form.

Beta-carotene (provitamin A) found in orange and yellow vegetables appears to reduce iron binding to inhibitors like phytates, making it a useful addition for those relying heavily on plant-based iron sources. Some researchers suggest that addressing vitamin A status alongside iron may be particularly important in populations where both deficiencies co-exist.

Organic acids such as citric acid, malic acid (in apples and pears), and tartaric acid also help keep non-haem iron soluble and available for absorption.

Absorption Inhibitors: The Hidden Blockers

Understanding inhibitors is just as important as understanding enhancers, because many commonly recommended "healthy" foods and beverages actively suppress iron uptake.

Tannins in tea and coffee bind iron into insoluble complexes in the gut lumen. A cup of black tea consumed with a meal can reduce non-haem iron absorption by up to 60–70%. Even herbal teas containing tannic compounds (peppermint, chamomile) may have a modest inhibitory effect. Waiting at least 60 minutes after a meal before drinking tea or coffee substantially reduces this interference.

Phytates (phytic acid) are found in whole grains, legumes, nuts, and seeds. They are among the most potent inhibitors of non-haem iron absorption. Soaking, sprouting, fermenting, or pressure cooking legumes and grains reduces phytate content significantly. Yeast-leavened wholegrain bread contains substantially less phytate than unleavened flatbreads because the fermentation process activates phytase enzymes.

Calcium competes with iron for absorption via DMT-1. Dairy products, calcium-fortified foods, and calcium supplements consumed at the same time as iron can reduce iron absorption by 30–50%. Separating iron supplementation from calcium intake by at least two hours is a practical strategy that many clinicians and supplement packages overlook.

Polyphenols from wine, grapes, berries, and some vegetables also inhibit iron absorption, though the effect varies considerably between compound and food matrix. This does not mean avoiding polyphenol-rich foods, their benefits are extensive, but it does argue for taking iron supplements away from polyphenol-heavy meals rather than with them.

Soy protein contains multiple inhibitory compounds including phytates and polyphenols, making soy-based foods particularly effective at reducing non-haem iron absorption.

Iron Supplement Forms: A Practical Comparison

The market offers a confusing array of iron compounds. They differ substantially in elemental iron content, tolerability, and actual absorption.

Ferrous sulphate is the oldest, cheapest, and most extensively studied oral iron form. It provides high elemental iron content (20% by weight) and reasonable absorption. However, it is notorious for gastrointestinal side effects (constipation, nausea, stomach cramps, and black stools) that cause many patients to discontinue supplementation before their stores are replenished. Controlled-release formulations reduce GI side effects but also reduce absorption, partially negating the benefit.

Ferrous bisglycinate (chelated iron) is a newer form where ferrous iron is bound to two glycine molecules. This chelation protects the iron from inhibitory compounds in the gut and allows it to be absorbed via a peptide transporter pathway that partially bypasses DMT-1. Clinical studies show ferrous bisglycinate achieves similar or better iron repletion compared to ferrous sulphate at lower elemental doses, with markedly fewer GI side effects. It is typically better tolerated by individuals who cannot manage ferrous sulphate, making adherence significantly higher in practice.

Iron polymaltose complex (IPC) is a non-ionic, stable iron-carbohydrate complex widely used in pregnancy and paediatric populations because of its excellent safety profile. Absorption is lower than ferrous salts and depends more heavily on iron status, it is released slowly and absorbed as needed, which is why it rarely causes the acute GI upset of ferrous sulphate. IPC is the form most frequently recommended for pregnant women in Australian clinical guidelines due to its tolerability and safety data.

Liposomal iron is the newest category, where iron is encapsulated within phospholipid vesicles (liposomes) that fuse directly with intestinal cell membranes, bypassing the luminal absorption step almost entirely. Preliminary evidence suggests liposomal iron achieves meaningful iron repletion at substantially lower doses than conventional forms, with minimal GI side effects. This is particularly promising for individuals with inflammatory bowel conditions, coeliac disease, or other absorptive disorders where luminal uptake is compromised. The evidence base is still growing, but early results are encouraging.

When considering bioavailability principles in supplementation, the central lesson applies across nutrients: the form of a compound often determines its clinical effectiveness as much as the dose printed on the label.

Hepcidin: Why Daily Dosing Often Backfires

Perhaps the most important and least-discussed factor in iron supplementation is hepcidin (a peptide hormone produced by the liver that acts as the master regulator of systemic iron. Hepcidin works by degrading ferroportin, the protein that exports iron from intestinal cells into the bloodstream. When hepcidin is high, dietary and supplemental iron is trapped inside intestinal cells and excreted when those cells shed) meaning it never reaches the bloodstream at all.

The problem is that a single dose of oral iron triggers a sharp rise in hepcidin within 4–6 hours that persists for 24 hours or more. This means that a second dose taken the next morning arrives in a hepcidin-elevated environment and is poorly absorbed. In women with normal iron stores or mild deficiency who are not severely depleted, daily supplementation may be largely wasted for the second day's dose.

A landmark study from the ETH Zurich group demonstrated that alternate-day iron dosing results in significantly higher fractional absorption per dose compared to daily dosing, precisely because hepcidin has time to return to baseline between doses. For women supplementing for iron repletion rather than acute treatment of severe deficiency, taking iron every other day, or even every third day, may achieve equivalent or better results with half the tablets and fewer side effects.

This has now been incorporated into supplementation guidance from several European nutrition bodies, though Australian clinical guidelines are slower to reflect it. Anyone currently on daily iron who is experiencing GI side effects or poor response should discuss alternate-day dosing with their healthcare provider.

Hepcidin is also elevated by inflammation (as part of the acute phase response), which is why iron supplementation is often ineffective in the setting of chronic illness, infection, or inflammatory bowel disease. In these contexts, the underlying inflammation must be addressed alongside supplementation, and intravenous iron is often more effective.

Intravenous Iron: When Oral Falls Short

For patients with true malabsorption, severe inflammatory conditions, post-surgical iron deficiency (particularly after bariatric surgery or bowel resection), or those who require rapid repletion (e.g., pre-operative anaemia), intravenous (IV) iron bypasses all of the absorption barriers discussed above. Modern IV iron formulations (ferric carboxymaltose, ferric derisomaltose, and iron sucrose) are safe and effective, with serious adverse events rare in appropriately selected patients.

The evidence clearly shows IV iron replenishes stores faster and more completely than oral iron in malabsorption settings. However, IV iron is not universally superior to optimised oral iron in patients with functional guts; it carries cost, access, and procedural burden. The decision to use IV iron should be individualised by a treating clinician.

Who Actually Needs to Supplement?

Iron requirements are highest during periods of menstrual blood loss, pregnancy, rapid growth, and endurance athletic training. In Australia, iron deficiency is particularly prevalent in:

• Women of reproductive age (estimated 12–15% of Australian women have iron deficiency, with a meaningful subset also anaemic)
• Pregnant women (requirements nearly double in the second and third trimester)
• Endurance athletes, particularly female runners (foot-strike haemolysis, sweat losses, and GI bleeding from running)
• Vegans and strict vegetarians (lower bioavailability of plant-based iron)
• Individuals with coeliac disease, inflammatory bowel disease, or other GI conditions affecting absorption
• Regular blood donors
• Adolescent females during the growth phase

Symptoms of iron deficiency (fatigue, poor concentration, cold intolerance, hair loss, restless legs, reduced exercise capacity) can appear well before frank anaemia develops. This is the stage of iron depletion where functional stores are low but haemoglobin is still maintained. Many women in this state are told their blood count is "normal" and are not offered supplementation.

Testing: Ferritin Is the Key Marker

Haemoglobin is an insensitive marker for early iron deficiency. By the time haemoglobin falls below the reference range, iron stores have typically been depleted for some time and functional symptoms are usually already present.

Ferritin, the iron storage protein, is the most useful single marker. However, laboratory reference ranges (often listed as "normal" from 15–300 µg/L) are calibrated to detect severe deficiency and iron overload, not to identify the functional state associated with optimal tissue iron. For ferritin and iron panel testing, the emerging evidence supports more clinically nuanced thresholds:

• Ferritin below 30 µg/L: likely iron deficiency; supplementation usually warranted
• Ferritin 30–50 µg/L: suboptimal; particularly symptomatic individuals benefit from supplementation
• Ferritin 50–100 µg/L: target range for most adults, associated with optimal energy and hair and cognitive function
• Ferritin above 100 µg/L: generally sufficient; supplementation unnecessary unless specific conditions apply
• Ferritin above 200 µg/L: warrants investigation, particularly in the absence of supplementation or haemochromatosis risk

Ferritin is also an acute phase reactant, it rises with inflammation even when iron stores are genuinely low. In individuals with chronic inflammation, a "normal" ferritin does not rule out functional iron deficiency. Combining ferritin with transferrin saturation (below 20% suggests deficiency) and soluble transferrin receptor levels provides a more complete picture.

Iron studies are best requested as a panel: serum iron, transferrin (or TIBC), transferrin saturation, and ferritin. A full blood count adds haemoglobin, MCV (low in iron deficiency), and red cell distribution width (elevated as iron deficiency progresses).

Connections to Methylation and Metabolism

Iron metabolism does not operate in isolation. Iron is required as a cofactor for multiple enzyme systems, including those involved in neurotransmitter synthesis and mitochondrial energy production. The relationship between methylation and iron metabolism is bidirectional, methylation status affects erythropoiesis, while iron availability affects folate and B12 utilisation pathways. Clinicians assessing refractory iron deficiency should consider broader nutritional assessment including B12, folate, and methylation markers.

For those navigating supplementation decisions within a broader wellness framework, understanding research-grade supplementation standards helps contextualise the quality and evidence thresholds that differentiate clinical-grade products from general retail supplements.

Practical Take-Home Points

For most women with iron deficiency confirmed by ferritin below 50 µg/L:

1. Choose ferrous bisglycinate if ferrous sulphate causes GI side effects, the tolerability difference is clinically significant and adherence matters more than marginal differences in elemental dose
2. Take iron with 200–500 mg vitamin C, on an empty stomach if tolerated, or with a light meal if not
3. Avoid tea, coffee, and calcium-rich foods within 60–90 minutes of the dose
4. Consider alternate-day dosing if daily supplementation causes ongoing GI discomfort or if response has been poor
5. Retest ferritin 8–12 weeks after starting supplementation; allow 3–6 months of consistent supplementation to fully replenish stores
6. Target ferritin 50–100 µg/L as the repletion endpoint, not merely "within normal range"
7. If supplementation repeatedly fails to improve ferritin, investigate absorption (coeliac screen, IBD assessment) and ongoing blood losses before escalating to IV iron

Iron deficiency is correctable, but only when the right form is chosen, inhibitors are managed, and the dosing strategy accounts for the biology of hepcidin. Most supplement failures trace back to one or more of these overlooked factors, not to a fundamental limitation of oral iron itself.

Frequently Asked Questions

Why do iron supplements often fail to correct deficiency?

Iron absorption varies by a factor of ten depending on the form, what you eat with it, your gut environment, and the hormone hepcidin. The non-haem iron in most supplements is absorbed at only 2–20%, and is readily blocked by tea, coffee, phytates, and calcium. A 100 mg non-haem tablet may deliver only 2–5 mg of absorbed iron in a poor context, which is why many people take iron for months and still feel exhausted.

What is the difference between haem and non-haem iron?

Haem iron, found in red meat, poultry, and fish, is absorbed at roughly 15–35% (mean ~25%) and its uptake is stable regardless of what else is on the plate. Non-haem iron, which dominates in plant foods and almost every supplement, must first be reduced from ferric to ferrous form and is absorbed at anywhere from 2% to 20% depending on the enhancers (vitamin C, the "meat factor") and inhibitors (tannins, phytates, calcium) present.

What is the best form of iron supplement?

Ferrous sulphate is cheap and well-studied but frequently causes GI side effects that end supplementation early. Ferrous bisglycinate (chelated) achieves similar or better repletion at lower elemental doses with markedly fewer side effects, so real-world adherence is higher. Iron polymaltose is gentle and favoured in pregnancy, and liposomal iron is a newer low-dose, well-tolerated option useful where gut absorption is compromised.

Why does alternate-day iron dosing work better than daily?

A single oral dose triggers a sharp rise in hepcidin within 4–6 hours that persists for over 24 hours, so a dose taken the next morning arrives in a hepcidin-elevated gut and is poorly absorbed. Research from ETH Zurich showed that alternate-day dosing produces significantly higher fractional absorption per dose, meaning equivalent or better repletion with half the tablets and fewer side effects.

What ferritin level should I aim for?

Standard lab ranges (often 15–300 µg/L) are calibrated to detect severe deficiency, not optimal tissue iron. More useful functional thresholds are: below 30 µg/L likely deficient, 30–50 suboptimal, 50–100 the target range for most adults, and above 200 worth investigating. Retest 8–12 weeks after starting and allow 3–6 months to fully replenish. Because ferritin rises with inflammation, a "normal" value does not rule out functional deficiency, pair it with transferrin saturation.